[Endotoxinemia and systemic inflammation in pathogenesis of chronic heart failure]

Area of Science:

• Microbiology
• Immunology
• Cardiology

Context:

• Chronic heart failure (CHF) is associated with systemic inflammation and altered matrix metalloproteinase (MMP) activity.
• The gut microbiome's role in cardiovascular disease is an emerging area of research.
• Endotoxinemia, resulting from gut barrier dysfunction, is implicated in various inflammatory conditions.

Purpose:

• To investigate the relationship between large intestine microbiocenosis, endotoxinemia, systemic inflammation markers, and the matrix metalloproteinase-tissue inhibitor of metalloproteinases (MMP-TIMP) system in patients with chronic heart failure (CHF).
• To explore the potential contribution of gut dysbiosis and associated inflammatory markers to the progression of CHF and myocardial extracellular matrix disturbances.

Summary:

• The study analyzed gut microbiota composition, endotoxinemia levels, and key inflammatory markers including tumor necrosis factor alpha, C-reactive protein, sE-selectin, MMP-9, and TIMP-4 in CHF patients.
• Findings indicate a significant association between gut dysbiosis, elevated endotoxinemia, heightened systemic inflammation, and an imbalanced MMP-TIMP system with the progression of CHF.
• This dysregulation is suggested to contribute to disturbances in myocardial extracellular matrix structure and adverse cardiac remodeling.

Impact:

• Highlights the gut microbiome as a potential therapeutic target for managing chronic heart failure.
• Provides insights into the mechanisms linking gut health, systemic inflammation, and cardiovascular remodeling.
• Suggests that targeting dysbiosis and endotoxinemia may help mitigate CHF progression and improve cardiac function.